Skip to main content
Premium Trial:

Request an Annual Quote

Kinaxo, Takeda Reach Second Collaboration

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Kinaxo Biotechnologies today announced a second collaboration with Takeda Pharmaceuticals to use its technology to assist in the development of drugs.

Under the agreement, German firm Kinaxo will employ its quantitative phosphoproteomics technology, PhosphoScout, in the research, allowing Takeda to make early educated decisions on drug efficacy and safety, Kinaxo said. PhosphoScout uses mass spectrometry methods to enable unbiased quantification of about 15,000 phosphorylation sites in one experiment.

Financial and other terms of the deal were not disclosed.

Kinaxo and Takeda inked an agreement in 2008 for use of Kinaxo's KinaTor chemical proteomics technology.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.